1. Home
  2. ARTL vs IXHL Comparison

ARTL vs IXHL Comparison

Compare ARTL & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTL
  • IXHL
  • Stock Information
  • Founded
  • ARTL 2011
  • IXHL 2001
  • Country
  • ARTL United States
  • IXHL Australia
  • Employees
  • ARTL N/A
  • IXHL N/A
  • Industry
  • ARTL Biotechnology: Pharmaceutical Preparations
  • IXHL
  • Sector
  • ARTL Health Care
  • IXHL
  • Exchange
  • ARTL Nasdaq
  • IXHL Nasdaq
  • Market Cap
  • ARTL 3.1M
  • IXHL 3.6M
  • IPO Year
  • ARTL N/A
  • IXHL N/A
  • Fundamental
  • Price
  • ARTL $1.05
  • IXHL $0.21
  • Analyst Decision
  • ARTL Strong Buy
  • IXHL
  • Analyst Count
  • ARTL 2
  • IXHL 0
  • Target Price
  • ARTL $5.50
  • IXHL N/A
  • AVG Volume (30 Days)
  • ARTL 47.0K
  • IXHL 143.6M
  • Earning Date
  • ARTL 05-13-2025
  • IXHL 05-15-2025
  • Dividend Yield
  • ARTL N/A
  • IXHL N/A
  • EPS Growth
  • ARTL N/A
  • IXHL N/A
  • EPS
  • ARTL N/A
  • IXHL N/A
  • Revenue
  • ARTL N/A
  • IXHL $98,000.00
  • Revenue This Year
  • ARTL N/A
  • IXHL $3,817.06
  • Revenue Next Year
  • ARTL N/A
  • IXHL $66.67
  • P/E Ratio
  • ARTL N/A
  • IXHL N/A
  • Revenue Growth
  • ARTL N/A
  • IXHL N/A
  • 52 Week Low
  • ARTL $0.82
  • IXHL $0.08
  • 52 Week High
  • ARTL $1.55
  • IXHL $3.55
  • Technical
  • Relative Strength Index (RSI)
  • ARTL 58.54
  • IXHL 44.41
  • Support Level
  • ARTL $0.90
  • IXHL $0.19
  • Resistance Level
  • ARTL $1.02
  • IXHL $0.31
  • Average True Range (ATR)
  • ARTL 0.07
  • IXHL 0.14
  • MACD
  • ARTL 0.01
  • IXHL 0.02
  • Stochastic Oscillator
  • ARTL 62.18
  • IXHL 13.27

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: